Top Markets
#1 PulseChain PulseChain +43.68%
#2 Bitway Bitway +9.64%
#3 Meteora Meteora +8.38%
#4 Velvet Velvet +7.60%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +7.15%
#6 eCash eCash +6.72%
#7 Fake World Assets Fake World Assets +6.06%
#8 Bitcoin SV Bitcoin SV +5.96%
#9 Cash Cat Cash Cat +5.45%
#10 Rocket Pool Rocket Pool +5.30%
Coin of the day
PulseChain PulseChain
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Resverlogix Corp. Resverlogix Corp.

Resverlogix Corp.

RVX
Classifica tra le azioni #28673
Resverlogix Corporation is a biotechnology firm currently in advanced clinical... Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Prezzo delle azioni
$0.07339369
Ultima sincronizzazione: 2026-08-18
Capitalizzazione di mercato
$25.24M
Variazione (1 giorno)
5.26%
Variazione (1 anno)
-7.44%
Paese
CA
Scambia Resverlogix Corp. (RVX)

Categoria

Healthcare
Ricavi di Resverlogix Corp. (RVX)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Resverlogix Corp., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Resverlogix Corp. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH